IRONWOOD PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $113.04M | $0.31 | $0.31 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $106.50M | $0.24 | $0.24 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | Before market open | $47.70M | $-0.01 | $-0.01 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $122.10M | $0.23 | $0.24 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $85.20M | $0.14 | $0.14 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $41.10M | $-0.23 | $-0.14 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $90.50M | $0.02 | $0.02 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $91.60M | $0.02 | $0.02 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| U.S. LINZESS Net Sales | 2026 | $1.15B to $1.20B | Raised |
| Total Revenue | 2026 | $460.00M to $485.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ironwood Pharmaceuticals filed with the SEC
Raises 2026 Full-Year Financial Guidance Building on
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Reports Strong First
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Provides Clinical and
Other events · EX-99.1 to Form 8-K
Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) –
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals A Leading GI Healthcare Company 1 NASDAQ: IRWD
Results of operations · EX-99.2 to Form 8-K
Pharmaceuticals Reports Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS ® U.S. Net Sales and Ironwood Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Ironwood and VectivBio Announce the Completion
Acquisition or disposition completed · New financial obligation · Other events · EX-99.1 to Form 8-K
FORM OF TENDER AND SUPPORT
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Ironwood Enters into Definitive Agreement to
Material agreement · New financial obligation · Other events · EX-99.2 to Form 8-K
Reports First Quarter 2023 Results; Maintains Full Year 2023
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Leading in GI through Growth and InnovationJ.P. Morgan Healthcare Conference | January 11, 2023Presented by Tom McCourtCEO, Ironwood Pharmaceuticals, Inc.Nasdaq: IRWD
Results of operations · EX-99.2 to Form 8-K
Ironwood Pharmaceuticals Reports Strong Third
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS ®
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1
Results of operations · EX-99.1 to Form 8-K
Ironwood Pharmaceuticals Provides Update on
Results of operations · EX-99.1 to Form 8-K
Reports Third Quarter 2021 Results and Provides Corporate Development Update
Results of operations · EX-99.1 to Form 8-K